Due to its xenobiotic effects on liver enzymes (Cyp450), the Nrf2-mediated antioxidant effects of Oltipraz has also shown significant liver accumulation and promise in the treatment of NASH. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.